Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BCX10013

Other · developed by BioCryst Pharmaceuticals

Phase 1 Most advanced trial (none active)

BCRX Developer

1 Registered trials

What is BCX10013?

BCX10013 is a drug name appearing in a trial registry entry that states only that multiple dose levels may be tested.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Hematology
Developer: BioCryst Pharmaceuticals (BCRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06100900	Phase 1	Paroxysmal Nocturnal Hemoglobinuria	Completed	BCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Paroxysmal Nocturnal Hemoglobinuria

More from BioCryst Pharmaceuticals

Berotralstat FDA approved Peramivir FDA approved Avoralstat Phase 3 BCX17725 Phase 1 Forodesine Phase 1/2 Galidesivir Phase 1 Pelecopan Phase 2 Ulodesine Phase 2

Sources

ClinicalTrials.gov NCT06100900

Updated Oct 11, 2026. Something wrong or missing? Report it on the BCRX page.

Follow BCRX, the company behind BCX10013

See BCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BCRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z